Award recordCONTRACT

SOFIE CO.

PIID 36C24525C0046· VHA· 245-NETWORK CONTRACT OFFICE 5 (36C245)· 6505 · DRUGS AND BIOLOGICALS· FY2025· $1,059,228 net obligations· UEI JV1AHJHGUGG3· VA

Description

DEOBLIGATE FUNDS - PYLARIFY (PIFLUFOLASTAT F18 INJECTION)

Base award description: PYLARIFY (PIFLUFOLASTAT F18 INJECTION)

First action · last action
2024-12-23 · 2026-05-21
Transactions
2
First transaction's obligation
$1,863,816
Base + all options value (sum of deltas)
$1,059,228
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
2
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 2 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$1,863,816$0Base award · 2024-12-23 · this action $1,863,816 · running total $1,863,816Modification P00001 · 2026-05-21 · this action -$804,588 · running total $1,059,228
  • Base2024-12-23+$1,863,816= $1,863,816
  • Mod P000012026-05-21-$804,588= $1,059,228
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2024-12-23+$1,863,816$1,863,816PYLARIFY (PIFLUFOLASTAT F18 INJECTION)
Mod P00001· FUNDING ONLY ACTION2026-05-21−$804,588$1,059,228DEOBLIGATE FUNDS - PYLARIFY (PIFLUFOLASTAT F18 INJECTION)

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI JV1AHJHGUGG3)

AwardOffice · PSC / listingNet obligationsFY
36C25526N0392255-NETWORK CONTRACT OFFICE 15 (36C255) · 6505 · DRUGS AND BIOLOGICALS$357,066FY2026
36C25526N0245255-NETWORK CONTRACT OFFICE 15 (36C255) · 6505 · DRUGS AND BIOLOGICALS$1,172,834FY2026
36C24226N0463242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS$624,017FY2026
36C24226N0388242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS$830,796FY2026
36C24226D0040242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS$0FY2026
36C25026P0310250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS$347,000FY2026

Other recipients under 6505 from 245-NETWORK CONTRACT OFFICE 5 (36C245) (most recent first)

AwardRecipientOfficeNet obligationsFY
36C24526N0840TAKEDA PHARMACEUTICALS AMERICA, INC.245-NETWORK CONTRACT OFFICE 5 (36C245)$19,139FY2026
36C24526N0839TAKEDA PHARMACEUTICALS AMERICA, INC.245-NETWORK CONTRACT OFFICE 5 (36C245)$38,360FY2026
36C24526N0837QOL MEDICAL LLC245-NETWORK CONTRACT OFFICE 5 (36C245)$16,945FY2026
36C24526N0835TAKEDA PHARMACEUTICALS AMERICA, INC.245-NETWORK CONTRACT OFFICE 5 (36C245)$34,605FY2026
36C24526N0834GALDERMA LABORATORIES, L.P.245-NETWORK CONTRACT OFFICE 5 (36C245)$16,960FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C24525C0046_3600_-NONE-_-NONE- · retrieved 2026-09-26.